Literature DB >> 22690977

Pulmonary arterial hypertension with plexogenic arteriopathy in enzyme-substituted Gaucher disease.

Michael A den Bakker, Katrien Grünberg, Anco Boonstra, Peter Th W van Hal, Carla E M Hollak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22690977     DOI： 10.1111/j.1365-2559.2012.04261.x

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


× No keyword cloud information.
  4 in total

Review 1.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

2.  Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.

Authors:  L van Dussen; E J Hendriks; J E M Groener; R G Boot; C E M Hollak; J M F G Aerts
Journal:  J Inherit Metab Dis       Date:  2014-05-16       Impact factor: 4.982

3.  Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease.

Authors:  Gillian C Goobie; Sandra M Sirrs; John Yee; John C English; Celine Bergeron; Roland Nador; John R Swiston; Pramod K Mistry; Wendy Paquin; Robert D Levy
Journal:  Respir Med Case Rep       Date:  2019-06-29

Review 4.  Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension.

Authors:  Mazen Al-Qadi; Barbara LeVarge; H James Ford
Journal:  Front Med (Lausanne)       Date:  2021-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.